Loading...

Natale Ronald

Title(s)Medical Director, Lung Cancer Program
Phone310-435-7511
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Southwest Oncology Group
    NIH/NCI U10CA058882Feb 1, 1993 - Dec 31, 2015
    Role: Co-Principal Investigator
    TESTING THE PREDICTIONS OF A HUMAN TUMOR CLONING ASSAY
    NIH/NCI R01CA038741Dec 1, 1984 - Nov 30, 1987
    Role: Principal Investigator
    Southwest Oncology Group
    NIH/NCI U10CA027057Jan 1, 1980 - Dec 31, 2015
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15; 24(12):2749-2757. PMID: 29559563.
      View in: PubMed
    2. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. PMID: 29056570.
      View in: PubMed
    3. Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer. 2017 10; 112:195-199. PMID: 29191595.
      View in: PubMed
    4. Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH, Mayo C, Chao GY, Obasaju C, Natale R. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 09; 18(5):480-488. PMID: 28365238.
      View in: PubMed
    5. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626. PMID: 28194539.
      View in: PubMed
    6. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 12; 11(12):2066-2081. PMID: 27575423.
      View in: PubMed
    7. Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Sep 15; 22(18):4574-84. PMID: 27076631.
      View in: PubMed
    8. Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015 Apr; 33(2):341-8. PMID: 25388939.
      View in: PubMed
    9. Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol. 2014 Nov; 9(11):1704-8. PMID: 25436803.
      View in: PubMed
    10. Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012 Oct; 78(1):57-62. PMID: 22809813.
      View in: PubMed
    11. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012; 2012:913848. PMID: 22482054; PMCID: PMC3312207.
    12. Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, Lipton A, Albain KS, Masters GA, Natale RB, Selaru P, Kim ST, Chao RC, Page RD. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):474-80. PMID: 21680048.
      View in: PubMed
    13. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Mar 10; 29(8):1059-66. PMID: 21282542.
      View in: PubMed
    14. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9. PMID: 21105991; PMCID: PMC3117124.
    15. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov 20; 28(33):4953-60. PMID: 20940188.
      View in: PubMed
    16. Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. PMID: 20737417; PMCID: PMC2994945.
    17. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009 May 15; 15(10):3600-9. PMID: 19447868.
      View in: PubMed
    18. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. PMID: 19349543; PMCID: PMC2684855.
    19. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol. 2009 May 20; 27(15):2523-9. PMID: 19332730.
      View in: PubMed
    20. Gandara DR, Lara PN, Natale R, Belani C. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. PMID: 18779609.
      View in: PubMed
    21. Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S128-30. PMID: 18520295.
      View in: PubMed
    22. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
      View in: PubMed
    23. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81. PMID: 17947484.
      View in: PubMed
    24. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5025-33. PMID: 17075122.
      View in: PubMed
    25. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. PMID: 16797779.
      View in: PubMed
    26. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. PMID: 16536755.
      View in: PubMed
    27. Lara PN, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. PMID: 16640809.
      View in: PubMed
    28. Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S23-9. PMID: 16459176.
      View in: PubMed
    29. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. PMID: 16087880; PMCID: PMC1187965.
    30. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. PMID: 15699478.
      View in: PubMed
    31. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 01; 23(13):2946-54. PMID: 15699477.
      View in: PubMed
    32. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004 Nov 15; 22(22):4456-62. PMID: 15483017.
      View in: PubMed
    33. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004 Sep; 45(3):381-6. PMID: 15301879.
      View in: PubMed
    34. Natale RB. Gemcitabine-containing regimens vs others in first-line treatment of NSCLC. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):27-31. PMID: 15339056.
      View in: PubMed
    35. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004 Jul 15; 22(14):2781-9. PMID: 15199091.
      View in: PubMed
    36. Natale RB. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Semin Oncol. 2004 Jun; 31(3 Suppl 9):23-30. PMID: 15206079.
      View in: PubMed
    37. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004 Mar 01; 22(5):777-84. PMID: 14990632.
      View in: PubMed
    38. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004 Mar 01; 22(5):785-94. PMID: 14990633.
      View in: PubMed
    39. Natale RB. Inhibition of epidermal growth factor receptor and symptom improvement in advanced non-small cell lung cancer. Semin Respir Crit Care Med. 2004; 25 Suppl 1:29-32. PMID: 16088518.
      View in: PubMed
    40. Natale RB. Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):39-43. PMID: 15142633.
      View in: PubMed
    41. Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):246s-252s. PMID: 14645404.
      View in: PubMed
    42. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22; 290(16):2149-58. PMID: 14570950.
      View in: PubMed
    43. Natale RB. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clin Lung Cancer. 2003 Sep; 5 Suppl 1:S11-7. PMID: 14641989.
      View in: PubMed
    44. Natale RB. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):22-6. PMID: 12886870.
      View in: PubMed
    45. Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer. 2002 Oct 01; 95(7):1520-7. PMID: 12237921.
      View in: PubMed
    46. Natale RB. Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer. 2002 Mar; 3 Suppl 1:S10-6. PMID: 14720349.
      View in: PubMed
    47. Natale RB, Zaretsky SL. ZD1839 (Iressa): what's in it for the patient? Oncologist. 2002; 7 Suppl 4:25-30. PMID: 12202785.
      View in: PubMed